Today, Abbott announced the start of European clinicals trial to evaluate its new Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the peripheral arteries. The Esprit drug eluting BVS is made of polylactide, the same biocompatible material used in the company's Absorb™ drug eluting BVS for coronary artery disease, which has been authorized for sale in Europe and is investigational in the United States. Esprit is designed to restore...
↧